Inozyme Pharma Statistics
Share Statistics
Inozyme Pharma has 64.24M shares outstanding. The number of shares has increased by 1.63% in one year.
| Shares Outstanding | 64.24M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.42% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 43.99M |
| Failed to Deliver (FTD) Shares | 23 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.23M, so 5.03% of the outstanding shares have been sold short.
| Short Interest | 3.23M |
| Short % of Shares Out | 5.03% |
| Short % of Float | 7.42% |
| Short Ratio (days to cover) | 14.61 |
Valuation Ratios
The PE ratio is -3.1 and the forward PE ratio is -2.32.
| PE Ratio | -3.1 |
| Forward PE | -2.32 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.57 |
| P/FCF Ratio | -3.11 |
| PEG Ratio | n/a |
Enterprise Valuation
Inozyme Pharma Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 13.36, with a Debt / Equity ratio of 0.33.
| Current Ratio | 13.36 |
| Quick Ratio | 13.36 |
| Debt / Equity | 0.33 |
| Total Debt / Capitalization | 24.54 |
| Cash Flow / Debt | -1.55 |
| Interest Coverage | -22.7 |
Financial Efficiency
Return on equity (ROE) is -0.51% and return on capital (ROIC) is -40.44%.
| Return on Equity (ROE) | -0.51% |
| Return on Assets (ROA) | -0.35% |
| Return on Capital (ROIC) | -40.44% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.21M |
| Employee Count | 59 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -24.88% in the last 52 weeks. The beta is 1.54, so Inozyme Pharma 's price volatility has been higher than the market average.
| Beta | 1.54 |
| 52-Week Price Change | -24.88% |
| 50-Day Moving Average | 3.97 |
| 200-Day Moving Average | 4.88 |
| Relative Strength Index (RSI) | 43.39 |
| Average Volume (20 Days) | 439.87K |
Income Statement
In the last 12 months, Inozyme Pharma had revenue of $0 and earned -$71.17M in profits. Earnings per share was $-1.37.
| Revenue | 0 |
| Gross Profit | -1.29M |
| Operating Income | -75.64M |
| Net Income | -71.17M |
| EBITDA | -74.81M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.37 |
Balance Sheet
The company has $34.59M in cash and $46.59M in debt, giving a net cash position of -$12.00M.
| Cash & Cash Equivalents | 34.59M |
| Total Debt | 46.59M |
| Net Cash | -12.00M |
| Retained Earnings | -285.93M |
| Total Assets | 143.36M |
| Working Capital | 122.59M |
Cash Flow
In the last 12 months, operating cash flow was -$70.67M and capital expenditures -$298.00K, giving a free cash flow of -$70.97M.
| Operating Cash Flow | -70.67M |
| Capital Expenditures | -298.00K |
| Free Cash Flow | -70.97M |
| FCF Per Share | -1.37 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
INZY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -45.36% |
| FCF Yield | -36.64% |
Analyst Forecast
The average price target for INZY is $14.5, which is 380.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.5 |
| Price Target Difference | 380.1% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -2.64 |
| Piotroski F-Score | 2 |